What are the pros and cons of first‑line pharmacologic treatments for moderate‑to‑severe depression in adults, including selective serotonin reuptake inhibitors (SSRIs), serotonin‑norepinephrine reuptake inhibitors (SNRIs), bupropion, and mirtazapine?

First-Line Pharmacologic Treatments for Moderate-to-Severe Depression in Adults

For moderate-to-severe depression, SSRIs remain the first-line choice due to their established efficacy, safety profile, and tolerability, though SNRIs (particularly venlafaxine), bupropion, and mirtazapine offer distinct advantages for specific symptom profiles and should be selected based on target symptoms rather than treating all patients identically. 1

Evidence-Based Comparison

SSRIs (Selective Serotonin Reuptake Inhibitors)

Pros:

• Efficacy: Demonstrated consistent effectiveness across multiple trials for acute and maintenance treatment 1
• Safety: Superior safety in overdose compared to older antidepressants 2
• Tolerability: Better tolerated than tricyclics, enhancing compliance 2
• Maintenance: Most consistent evidence for relapse prevention in long-term treatment 3
• Comorbidity: Effective for anxious depression, dysthymia, and atypical depression 2

Cons:

• Delayed onset: Significant therapeutic effect takes 2+ weeks 4
• Sexual dysfunction: High rates of arousal disorder, orgasmic dysfunction, and decreased libido 5
• GI effects: Nausea and diarrhea common, especially at initiation 5
• Limited efficacy domains: Poor treatment of anhedonia and cognitive impairment 4
• Initial anxiety: Can worsen anxiety symptoms when starting treatment 4
• Sleep disturbance: May cause or worsen insomnia 4

SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

Pros:

• Superior efficacy in severe depression: Venlafaxine and duloxetine show greater efficacy than SSRIs in moderate-to-severe depression 6
• Faster onset: Demonstrated superiority at 2 weeks compared to SSRIs 7
• Noradrenergic symptoms: Better for patients with underactive noradrenergic activity 8
• Maintenance: Consistent evidence for relapse prevention 3

Cons:

• Greater side-effect burden: More adverse events than SSRIs 6
• Discontinuation: Higher rates of adverse events leading to treatment discontinuation 1
• Sexual dysfunction: Similar rates to SSRIs 5
• Not universal: Milnacipran shows no superiority over SSRIs 6

Bupropion

Pros:

• Sexual function: Significantly lower rates of sexual dysfunction (arousal disorder RR 0.46, orgasmic dysfunction RR 0.22, desire disorder RR 0.65) 5
• GI tolerability: Lower rates of nausea (RR 0.6) and diarrhea (RR 0.31) 5
• Sedation: Less somnolence (RR 0.27) compared to SSRIs 5
• Specific symptoms: Most effective for hypersomnia, increased weight/appetite, and fatigue 9
• Efficacy: Equivalent effectiveness to SSRIs in depression response 5, 10
• Maintenance: Demonstrated efficacy in preventing relapse over 44 weeks 10

Cons:

• Seizure risk: Dose-dependent seizure risk, contraindicated in seizure disorders 10
• Drug interactions: CYP2D6 inhibitor, increases levels of drugs metabolized by this pathway 2-5 fold 10
• Limited anxiety treatment: Not ideal for anxious depression
• Activation: May worsen anxiety or agitation in some patients

Mirtazapine

Pros:

• Faster onset: Superior to SSRIs at 2 weeks (OR 1.57) and end of acute treatment (OR 1.19) 11
• Sleep: Most effective for insomnia, decreased weight, and decreased appetite 9
• Anxiety: Effective for anxious depression
• GI tolerability: Lower rates of nausea/vomiting than SSRIs 11
• Sexual function: Lower rates of sexual dysfunction than SSRIs 11
• Efficacy: Equivalent or superior to tricyclics and SSRIs 11

Cons:

• Weight gain: Significantly more likely to cause weight gain and increased appetite 11
• Sedation: High rates of somnolence, particularly problematic during daytime 11
• Metabolic effects: Concerns about long-term metabolic consequences
• Dropout rates: Similar overall dropout rates despite different adverse event profile 11

Clinical Decision Algorithm

Step 1: Assess Target Symptoms

• Hypersomnia, weight gain, fatigue → Choose bupropion 9
• Insomnia, weight loss, poor appetite → Choose mirtazapine 9
• Severe depression with anxiety → Choose SNRI (venlafaxine/duloxetine) 6, 8
• Sexual dysfunction concerns → Choose bupropion (first) or mirtazapine (second) 5, 11
• Standard presentation without specific targets → Choose SSRI 1, 3

Step 2: Consider Contraindications

• Seizure history/risk → Avoid bupropion 10
• Significant drug interactions (CYP2D6 substrates) → Avoid bupropion 10
• Metabolic syndrome/obesity → Avoid mirtazapine 11
• Need for rapid onset → Prefer mirtazapine or SNRI over SSRI 11, 7

Step 3: Severity-Based Selection

• Moderate depression → SSRI or bupropion acceptable 1
• Severe depression → Prefer SNRI (venlafaxine/duloxetine) over SSRI 6, 8
• Treatment-resistant → Consider augmentation strategies (not monotherapy comparison) 1

Critical Pitfalls to Avoid

1. Underdosing bupropion: Efficacy demonstrated at 450 mg/day, not lower doses 10
2. Ignoring symptom profiles: Network meta-analyses show similar aggregate efficacy but meaningful symptom-specific differences exist 9
3. Premature switching: Allow adequate trial duration (6-8 weeks) before declaring treatment failure 1
4. Overlooking adverse events: Discontinuation due to adverse events is higher with antidepressants than most nonpharmacologic treatments 1
5. Assuming class equivalence: Within SNRIs, only venlafaxine and duloxetine show superiority over SSRIs; milnacipran does not 6

Important Nuances

The 2023 American College of Physicians systematic review found that benefits appear similar among first-line treatments, but the certainty of evidence is low for most comparisons 1. This means clinicians should focus on:

• Options with the most reliable evidence (SSRIs, venlafaxine, mirtazapine)
• Adverse event profiles that match patient tolerance
• Symptom-specific targeting rather than generic "depression treatment"

The key insight from recent evidence is that aggregate outcomes (total severity scores, remission rates) obscure clinically meaningful differences in symptom-level responses 9. Bupropion and mirtazapine consistently demonstrate complementary symptom profiles across independent trials, suggesting mechanism-based selection is superior to random first-line choice 9.